Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

4301 items (4301 unread) in 74 feeds

Acinar Cell Carcinoma (73 unread)

• Google - Acinar Cell Carcinoma (57 unread)
• PubMed - Acinar Cell Carcinoma (16 unread)
• Trial - Acinar Cell Carcinoma

Acinic Cell Carcinoma (53 unread)

• Google - Acinic Cell Carcinoma (36 unread)
• PubMed - Acinic Cell Carcinoma (17 unread)
• Trial - Acinic Cell Carcinoma

Adenoid Cystic Carcinoma (264 unread)

• Google - Adenoid Cystic Carcinoma (52 unread)
• PubMed - Adenoid Cystic Carcinoma (212 unread)
• Trial - Adenoid Cystic Carcinoma

Adrenal Gland Cancer (299 unread)

• Google - Adrenal Cancer (69 unread)
• Google - Adrenocortical Carcinoma (57 unread)
• PubMed - Adrenal Cancer (118 unread)
• PubMed - Adrenocortical Carcinoma (44 unread)
• Trial - Adrenal Cancer (9 unread)
• Trial - Adrenocortical Carcinoma (2 unread)

Ampulla Of Vater (55 unread)

• Google - Ampullary Cancer (38 unread)
• PubMed - Ampullary Cancer (15 unread)
• Trial - Ampullary Carcinoma (2 unread)

Anal Cancer (374 unread)

• Google - Anal Cancer (128 unread)
• PubMed - Anal Cancer (228 unread)
• Trial - Anal Cancers (18 unread)

Angiosarcoma (75 unread)

• Google - Angiosarcoma (46 unread)
• PubMed - Angiosarcoma (29 unread)
• Trial - Angiosarcoma

Appendix Cancer (95 unread)

• Google - Appendix Cancer (62 unread)
• PubMed - Appendix Cancer (27 unread)
• Trial - Appendix Cancer (6 unread)

Bile Duct Cancer (420 unread)

• Google - Bile Duct Cancer (41 unread)
• Google - Cholangiocarcinoma (64 unread)
• PubMed - Bile Duct Cancer (89 unread)
• PubMed - Cholangiocarcinoma (182 unread)
• Trial - Bile Duct Cancer (24 unread)
• Trial - Cholangiocarcinoma (20 unread)

Brain and CNS (464 unread)

• Google - Rare Brain Tumor (47 unread)
• Google - Rare CNS Tumor (125 unread)
• PubMed - Ganglioglioma (12 unread)
• PubMed - Rare Brain Tumor (99 unread)
• PubMed - Rare CNS Tumor (62 unread)
• Trial - Brain Tumor (67 unread)
• Trial - CNS Tumor (52 unread)
• Trial - Ganglioglioma

Carcinoid (70 unread)

• Google - Carcinoid (29 unread)
• PubMed - Carcinoid (40 unread)
• Trials - Carcinoid (1 unread)

Endocrine/Neuroendocrine (637 unread)

• Google - Merkel Cell Cancer (42 unread)
• Google - Neuroendocrine Tumor (40 unread)
• PubMed - Merkel Cell Cancer (25 unread)
• PubMed - Neuroendocrine Tumor (484 unread)
• Trial - Merkel Cell Cancer (3 unread)
• Trial - Neuroendocrine Cancers (43 unread)

Gall Bladder Cancer (90 unread)

• Google - Gall Bladder Cancer (43 unread)
• PubMed - Gall Bladder Cancer (40 unread)
• Trials - Gall Bladder Cancer (7 unread)

Hemangioendothelioma (149 unread)

• Google - Hemangioendothelioma (25 unread)
• PubMed - Hemangioendothelioma (122 unread)
• Trial - Hemangioendothelioma (2 unread)

Hepatoblastoma (67 unread)

• Google - Hepatoblastoma (35 unread)
• PubMed - Hepatoblastoma (29 unread)
• Trial - Hepatoblastoma (3 unread)

Pancreas (72 unread)

• Google - Insulinoma (51 unread)
• PubMed - Insulinoma (21 unread)
• Trial - Insulinoma

Phyllodes (61 unread)

• Google - Phyllodes Tumor (45 unread)
• PubMed - Phyllodes Tumor (16 unread)
• Trial - Phyllodes

PMP and Mucinous Tumors (79 unread)

• Google - Pseudomyxoma Peritonei (72 unread)
• PubMed - Pseudomyxoma Peritonei (PMP) (6 unread)
• Trial - Pseudomyxoma Peritonei (1 unread)

Rhabdomyosarcoma (96 unread)

• "rhabdomyosarcoma" - Google News (41 unread)
• PubMed - Rhabdomyosarcoma (49 unread)
• Trial - Rhabdomyosarcoma (6 unread)

Sarcoma (808 unread)

• "sarcoma" - Google News (109 unread)
• PubMed - Sarcoma (596 unread)
• Trial - Sarcoma (103 unread)

Trial - Cholangiocarcinoma (20 unread)

• 

  Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

  Posted: January 25th, 2023, 3:00pm GMT

  Condition:   Cholangiocarcinoma
  Interventions:   Drug: Carrelizumab;   Drug: Solfantinib
  Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
  Not yet recruiting
• 

  Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma

  Posted: January 23rd, 2023, 3:00pm GMT

  Condition:   Cholangiocarcinoma
  Intervention:  
  Sponsor:   Power Life Sciences Inc.
  Not yet recruiting
• 

  Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

  Posted: January 12th, 2023, 3:00pm GMT

  Conditions:   Hepatocellular Carcinoma;   Fibrolamellar Hepatocellular Carcinoma;   Cholangiocarcinoma, Perihilar;   Intrahepatic Cholangiocarcinoma;   Metastasis to Liver;   Gallbladder Carcinoma
  Intervention:   Other: ADBoard
  Sponsors:   Charite University, Berlin, Germany;   German Research Center for Artificial Intelligence
  Not yet recruiting
• 

  KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)

  Posted: January 11th, 2023, 3:00pm GMT

  Condition:   Esophageal Neoplasms
  Intervention:   Diagnostic Test: KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
  Sponsors:   Wuhan Ammunition Life-tech Co., Ltd;   Changhai Hospital
  Not yet recruiting
• 

  Biomarkers/ctDNA in Locally Advanced Cholangiocarcinoma

  Posted: January 10th, 2023, 3:00pm GMT

  Condition:   Locally Advanced Cholangiocarcinoma
  Intervention:  
  Sponsor:   CHA University
  Not yet recruiting
• 

  A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

  Posted: January 10th, 2023, 3:00pm GMT

  Condition:   Intrahepatic Cholangiocarcinoma (ICC)
  Intervention:   Drug: ICP-192
  Sponsor:   Beijing InnoCare Pharma Tech Co., Ltd.
  Recruiting
• 

  Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma

  Posted: January 10th, 2023, 3:00pm GMT

  Conditions:   Hilar Cholangiocarcinoma;   Intrahepatic Cholangiocarcinoma;   Common Bile Duct Neoplasms;   Cholangiocarcinoma;   Adenocarcinoma
  Intervention:   Procedure: Endoscopic Ultrasound registration
  Sponsor:   Erasmus Medical Center
  Recruiting
• 

  Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

  Posted: January 5th, 2023, 3:00pm GMT

  Conditions:   Durvalumab;   Intrahepatic Cholangiocarcinoma;   Gemcis
  Interventions:   Drug: Durvalumab;   Procedure: Surgery;   Drug: Gemcitabine;   Drug: Cisplatin
  Sponsor:   Tianjin Medical University Cancer Institute and Hospital
  Recruiting
• 

  Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

  Posted: December 19th, 2022, 3:00pm GMT

  Conditions:   Bile Duct Cancer;   Cholangiocarcinoma;   Cholangiocarcinoma Non-resectable;   Cholangiocarcinoma Metastatic;   Metastatic Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Durvalumab;   Radiation: Yttrium-90
  Sponsors:   Dana-Farber Cancer Institute;   AstraZeneca;   Sirtex Medical
  Not yet recruiting
• 

  Advanced or Metastatic Cholangiocarcinoma

  Posted: December 16th, 2022, 3:00pm GMT

  Condition:   Cholangiocarcinoma
  Interventions:   Drug: Carrilizumab;   Drug: Albumin-bound paclitaxel;   Drug: Apatinib
  Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
  Not yet recruiting
• 

  M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

  Posted: March 18th, 2022, 2:00pm GMT

  Conditions:   Metastatic Colorectal Cancer (Mcrc);   Intrahepatic Cholangiocarcinoma (Icc);   Colorectal Cancer;   Colorectal Neoplasms;   Cholangiocarcinoma;   Intrahepatic Bile Duct Cancer;   Bile Duct Cancer;   Bile Duct Neoplasms
  Interventions:   Drug: Floxuridine;   Drug: 5-Fluorouracil;   Drug: Irinotecan;   Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP);   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: M9241;   Drug: Gemcitabine;   Drug: Dexamethasone
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• 

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  Posted: February 16th, 2022, 3:00pm GMT

  Conditions:   Solid Tumor, Adult;   Intrahepatic Cholangiocarcinoma;   Urothelial Carcinoma
  Intervention:   Drug: KIN-3248
  Sponsor:   Kinnate Biopharma
  Recruiting
• 

  Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

  Posted: August 11th, 2021, 2:00pm GMT

  Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
  Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
  Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
  Recruiting
• 

  LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

  Posted: December 14th, 2020, 3:00pm GMT

  Conditions:   Metastatic Cancer;   Solid Tumor;   Pancreatic Cancer;   Urothelial Carcinoma;   Head and Neck Cancer;   Colorectal Cancer
  Interventions:   Drug: LYT-200;   Drug: Tislelizumab;   Drug: Gemcitabine/nab-paclitaxel
  Sponsor:   PureTech
  Recruiting
• 

  Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

  Posted: September 28th, 2020, 2:00pm GMT

  Conditions:   Bile Duct Cancer;   Biliary Cancer;   Biliary Tract Neoplasms;   Cholangiocarcinoma
  Interventions:   Drug: Trametinib;   Drug: Hydroxychloroquine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• 

  Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

  Posted: September 23rd, 2020, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer;   Intrahepatic Cholangiocarcinoma;   Perihilar Cholangiocarcinoma;   Extrahepatic Cholangiocarcinoma;   Hilar Cholangiocarcinoma;   Distal Bile Duct Cancer
  Intervention:   Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
  Sponsors:   University of Washington;   Natera, Inc.;   SEngine Precision Medicine, Inc.
  Recruiting
• 

  National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

  Posted: October 30th, 2019, 2:00pm GMT

  Conditions:   Hepatocellular Carcinoma;   Liver Cancer;   Cholangiocarcinoma
  Intervention:  
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• 

  Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

  Posted: September 12th, 2019, 2:00pm GMT

  Condition:   Intrahepatic Cholangiocarcinoma
  Intervention:   Drug: derazantinib
  Sponsor:   Basilea Pharmaceutica
  Available
• 

  Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

  Posted: April 23rd, 2019, 2:00pm GMT

  Conditions:   Metastatic Breast Carcinoma;   Locally Advanced Breast Cancer;   Cancer of Pancreas;   Solid Tumor With Intermediate or High HER2 Expression;   Salivary Gland Cancer;   Gastric Cancer;   Endometrial Cancer;   Uterine Cancer;   Non Small Cell Lung Cancer;   Biliary Tract Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Urothelial Carcinoma;   Prostate Cancer
  Intervention:   Drug: 68GaNOTA-Anti-HER2 VHH1
  Sponsors:   Universitair Ziekenhuis Brussel;   Kom Op Tegen Kanker;   Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.
  Recruiting
• 

  Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

  Posted: December 11th, 2015, 3:00pm GMT

  Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
  Intervention:   Biological: pembrolizumab
  Sponsor:   Merck Sharp & Dohme LLC
  Recruiting